Haematologica (Roma), 2016-07, Vol.101 (7), p.e295-e298
- Brown, Jennifer R
- Harb, Wael A
- Hill, Brian T
- Gabrilove, Janice
- Sharman, Jeff P
- Schreeder, Marshall T
- Barr, Paul M
- Foran, James M
- Miller, Thomas P
- Burger, Jan A
- Kelly, Kevin R
- Mahadevan, Daruka
- Ma, Shuo
- Li, Yan
- Pierce, Daniel W
- Barnett, Evelyn
- Marine, Jeffrey
- Miranda, Monika
- Azaryan, Ada
- Yu, Xujie
- Nava-Parada, Pilar
- Mei, Jay
- Kipps, Thomas J
2016
Details
- Autor(en) / Beteiligte
- Brown, Jennifer R
- Harb, Wael A
- Hill, Brian T
- Gabrilove, Janice
- Sharman, Jeff P
- Schreeder, Marshall T
- Barr, Paul M
- Foran, James M
- Miller, Thomas P
- Burger, Jan A
- Kelly, Kevin R
- Mahadevan, Daruka
- Ma, Shuo
- Li, Yan
- Pierce, Daniel W
- Barnett, Evelyn
- Marine, Jeffrey
- Miranda, Monika
- Azaryan, Ada
- Yu, Xujie
- Nava-Parada, Pilar
- Mei, Jay
- Kipps, Thomas J
- Titel
- Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
- Ist Teil von
- Haematologica (Roma), 2016-07, Vol.101 (7), p.e295-e298
- Ort / Verlag
- Italy: Ferrata Storti Foundation
- Erscheinungsjahr
- 2016
- Link zum Volltext
- Quelle
- EZB Electronic Journals Library
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0390-6078eISSN: 1592-8721DOI: 10.3324/haematol.2015.140806Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5004476
- Format
- –
- Schlagworte
- Acrylamides - administration & dosage, Acrylamides - adverse effects, Adult, Agammaglobulinaemia Tyrosine Kinase, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell - enzymology, Leukemia, Lymphocytic, Chronic, B-Cell - mortality, Male, Middle Aged, Online Only, Protein-Tyrosine Kinases - antagonists & inhibitors, Pyrimidines - administration & dosage, Pyrimidines - adverse effects, Recurrence, Survival Rate